Last reviewed 11 May 2022
From 14 October 2022, companies will be expected to comply with new changes to REACH information requirements.
ECHA explains the changes include the following.
Requirements and specific rules for adaptation of:
in vitro and in vivo mutagenicity studies, specifying when further studies are needed based on mutagenicity concerns
reproductive toxicity studies, specifying the preferred animal species and administration routes, and clarifying the conditions triggering the need for further studies based on concerns
aquatic toxicity studies, clarifying when long-term studies must be performed instead of short-term studies or in addition to them
toxicity studies on terrestrial and sediment organisms, specifying when long-term studies are needed instead of short-term studies and clarifying that long-term testing must investigate both degradation and transformation products
degradation and bioaccumulation studies, specifying when further testing is needed, including investigation of both degradation and transformation products.
The obligation for only representatives to provide details on the non-EU manufacturer they represent.
Substance identification information including:
the requirement to describe the compositions, nanoform or set of similar nanoforms related to information submitted to fulfil information requirements under Annex VII-X of REACH
new requirements for reporting a crystal structure and for reporting compositions for substances with unknown or variable composition, complex reaction products or of biological materials (UVCBs)
clarified requirements for reporting constituents, impurities, and additives as well as for analytical information.
More information can be found on ECHA’s website.